AdvaMed Statement on Final TCET Notice

WASHINGTON – AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker on the final Transitional Coverage for Emerging Technologies (TCET) notice from the Centers for Medicare and Medicaid Services (CMS):

“The final TCET notice is a step toward a stronger, more robust policy, but doesn’t go far enough to help the Medicare seniors depending on breakthrough diagnostics and treatments to alleviate their suffering. The limited number of devices CMS can handle demonstrates clearly to Congress the need for greater resources at CMS. And the exclusion of diagnostics is disappointing, particularly considering the potential for a breakthrough diagnostic technology to save not only lives but costs to the health care system overall through earlier detection. While we appreciate that CMS has released the rule, we call on Congress to finish the job by passing HR 1691, the Ensuring Access to Critical Breakthrough Products Act. Too many patients in need of breakthrough diagnoses and treatments are counting on it.”

Read at AdvaMed: https://www.advamed.org/industry-updates/news/advamed-statement-on-final-tcet-notice/

CMS released the TCET Final Notice; its text is here.

< Older Post

Newer Post >

Georgia Life Sciences designates City of Brookhaven as newest BioReady® Gold Community

February 20, 2026

Recognition highlights Brookhaven’s commitment to life sciences growth and biomanufacturing readiness Brookhaven, GA, Feb. 18, 2026 – The City of Brookhaven has been designated a BioReady Gold Community by Georgia Life Sciences, the state’s leading life sciences membership organization. The BioReady Community program evaluates a community’s preparedness to support life sciences development across key areas, including zoning and permitting, utilities and infrastructure, workforce readiness, and coordination among local government and economic development partners. The Gold distinction represents a high level of readiness and alignment with industry needs. “Achieving Gold BioReady status underscores Brookhaven’s commitment to being a competitive destination for life sciences innovation and manufacturing,” said Aaron Szarowicz, City of Brookhaven Economic Development Director. “This designation reflects the intentional investments and partnerships we’ve built to support companies as they scale and create high-quality jobs in our community.” Brookhaven’s BioReady assessment highlighted the City’s modern infrastructure, strategic location within metro Atlanta, access to a skilled workforce, and collaborative approach between City leadership, regional partners, and the business community. Together, these assets position Brookhaven to support companies across the life sciences value chain—from research and development to scale-up and manufacturing. The BioReady rating system evaluates communities across three tiers—Bronze, Silver, and Gold—based on their readiness to attract and support life sciences facilities. Through these ratings, Georgia Life Sciences helps municipalities better showcase biotech-zoned sites, strengthen infrastructure planning, and clearly identify life sciences-friendly locations. This approach enables communities like Brookhaven to compete more effectively for private investment and job creation. Georgia Life Sciences works to advance innovation, strengthen the workforce pipeline, and grow Georgia’s life sciences economy through the BioReady Community program, modeled after MassBio’s nationally recognized rating system which assesses a community’s readiness to host life sciences facilities based on zoning practices and infrastructure capacity. For more information on the non-profit, membership-based organization, visit www.galifesciences.org . For more information about Brookhaven’s economic development initiatives, visit www.BrookhavenGA.gov/EconDev . ### Media Contact: Ann Marie Quill, Assistant Communications Director 404-205-3832 AnnMarie.Quill@BrookhavenGA.gov